Last reviewed · How we verify

NCT03904862

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Terminated Phase 1, PHASE2 Last updated 30 October 2025
What this trial tests

Phase 1, PHASE2 trial testing CX 4945 in Medulloblastoma, Childhood in 21 participants. Terminated before completion.

Timeline
25 July 2019
Primary endpoint
11 August 2025
11 August 2025

Quick facts

Lead sponsorPediatric Brain Tumor Consortium
PhasePhase 1, PHASE2
StatusTerminated
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment21
Start date25 July 2019
Primary completion11 August 2025
Estimated completion11 August 2025
Sites12 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Pediatric Brain Tumor Consortium

Who can join

3 and older, any sex, with Medulloblastoma, Childhood or Medulloblastoma Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi center, Phase I, Phase II and surgical study of the CX-4945 drug (silmitasertib sodium) for patients with recurrent SHH (Sonic Hedgehog) medulloblastoma

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Protein kinase CK2: a potential therapeutic target for diverse human diseases.
    Borgo C, D'Amore C, Sarno S, Salvi M, et al · · 2021 · cited 273× · PMID 33994545 · DOI 10.1038/s41392-021-00567-7
  2. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
    D'Amore C, Borgo C, Sarno S, Salvi M. · · 2020 · cited 74× · PMID 33052585 · DOI 10.1007/s13402-020-00566-w
  3. The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities.
    Boni J, Rubio-Perez C, López-Bigas N, Fillat C, et al · · 2020 · cited 68× · PMID 32751160 · DOI 10.3390/cancers12082106
  4. CK2 Regulation: Perspectives in 2021.
    Roffey SE, Litchfield DW. · · 2021 · cited 63× · PMID 34680478 · DOI 10.3390/biomedicines9101361
  5. New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression.
    Bhatia S, Wang P, Toh A, Thompson EW. · · 2020 · cited 63× · PMID 32391381 · DOI 10.3389/fmolb.2020.00071
  6. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches.
    Menyhárt O, Győrffy B. · · 2020 · cited 60× · PMID 31970590 · DOI 10.1007/s10555-020-09854-1
  7. The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target.
    Rammohan M, Harris E, Bhansali RS, Zhao E, et al · · 2022 · cited 49× · PMID 35220406 · DOI 10.1038/s41388-022-02245-6
  8. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
    Huang D, Chowdhury S, Wang H, Savage SR, et al · · 2021 · cited 48× · PMID 35028612 · DOI 10.1016/j.xcrm.2021.100471

Verify or expand the search:

Other recruiting trials for Medulloblastoma, Childhood

Currently open trials in the same condition.

Other Pediatric Brain Tumor Consortium trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03904862.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing